Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth-quarter 2025 investor letter.

Astrazeneca (AZN) closed at $96.34 in the latest trading session, marking a +1.94% move from the prior day. The stock ...

The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...

The Nasdaq-100 Index is a globally recognized index that tracks the performance of 100 of the largest non-financial companies ...

Walmart (WMT) stock joins the Nasdaq-100 on Jan. 20, 2026, replacing AstraZeneca (AZN) stock—potentially driving $19B in ...

Investing.com - Guggenheim has reiterated its Buy rating on AstraZeneca (NASDAQ:AZN) (AZN:LN) with a price target of ...

AstraZeneca (NASDAQ:AZN) used its presentation at the J.P. Morgan Healthcare Conference to highlight strong 2025 performance, a growing late-stage pipeline, and management’s confidence in sustaining ...

AstraZeneca's shares jumped after Pfizer's announcement of a major deal with the Trump administration. Pfizer's good news could benefit AstraZeneca, too. Pfizer CEO Albert Bourla appeared with ...

AstraZeneca Plc (NASDAQ: AZN) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent ...

On Wednesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 program. The trial showed that anselamimab, a light chain ...